Quadrant Capital Group LLC Reduces Stock Holdings in Haleon PLC Sponsored ADR $HLN

Quadrant Capital Group LLC reduced its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 28.9% in the second quarter, HoldingsChannel reports. The firm owned 120,880 shares of the company’s stock after selling 49,050 shares during the quarter. Quadrant Capital Group LLC’s holdings in Haleon were worth $1,251,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Brighton Jones LLC bought a new stake in Haleon during the fourth quarter valued at approximately $187,000. AE Wealth Management LLC boosted its stake in shares of Haleon by 6.5% during the 1st quarter. AE Wealth Management LLC now owns 19,323 shares of the company’s stock worth $199,000 after acquiring an additional 1,186 shares during the last quarter. Cetera Investment Advisers boosted its stake in shares of Haleon by 17.8% during the 1st quarter. Cetera Investment Advisers now owns 164,390 shares of the company’s stock worth $1,692,000 after acquiring an additional 24,876 shares during the last quarter. Assetmark Inc. grew its position in shares of Haleon by 895.7% during the 1st quarter. Assetmark Inc. now owns 19,387 shares of the company’s stock valued at $199,000 after acquiring an additional 17,440 shares during the period. Finally, Pacer Advisors Inc. increased its stake in shares of Haleon by 10.5% in the 1st quarter. Pacer Advisors Inc. now owns 37,311 shares of the company’s stock worth $384,000 after purchasing an additional 3,532 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 16th. Finally, The Goldman Sachs Group raised Haleon from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Haleon currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Trading Down 1.8%

Shares of HLN stock opened at $9.59 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The stock has a fifty day simple moving average of $9.30 and a two-hundred day simple moving average of $9.85. The firm has a market capitalization of $42.69 billion, a PE ratio of 24.58, a PEG ratio of 3.00 and a beta of 0.20. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.